血清乙型肝炎核心相关抗原作为良好的替代品 肝内共价闭合

StephenW

577
Serum hepatitis B core-related antigen as a good surrogate
marker of intrahepatic covalently closed circular
DNA during different phases of chronic hepatitis B virus
infection
En-Qiang Chen1,2, Shu Feng3, Ling-Bo Liang1,2, Ling-Yun Zhou1,2,
Ling-Yao Du1,2, Li-Bo Yan1,2, Meng-Lan Wang1,2, Chuan-Min Tao3,
Hong Tang1,2; 1Center of Infectious Diseases, West China Hospital
of Sichuan University, Chengdu, China; 2Division of Infectious
Diseases, State Key Laboratory of Biotherapy, Sichuan University,
Chengdu, China; 3Department of Laboratory Medicine, West
China Hospital, Sichuan University, Chengdu, China
Aim: This study aimed to investigate the correlation of serum
quantitative hepatitis B core-related antigen (qHBcrAg) with
intrahepatic cccDNA in the different phases of the natural
history of chronic hepatitis B (CHB), and thus reveal whether
serum qHBcrAg could be used as an surrogate marker of intrahepatic
cccDNA. Methods: A total of 139 CHB patients who
underwent liver biopsy were enrolled, consisting of 59 patients
in immune tolerance (IT) phase, 52 patients in immune clearance
(IC) phase, 20 patients in low-replication (LR) phase, and
8 patients in reactivation phase. All patients in IC phase have
received entecavir (ETV) therapy, and 32 of them undergone
a second liver biopsy at 24 months. In this study, the serum
qHBcrAg, qHBsAg, HBV DNA and intrahepatic cccDNA levels
were all quantitatively measured. Results: Among the 139
patients, serum qHBcrAg was strongly positive correlated with
intrahepatic cccDNA (r=0.929, P<0.001), which is superior
to that of serum qHBsAg (r=0.742, P<0.001) and HBV DNA
(r=0.854, P<0.001) with intrahepatic cccDNA. And similar
interesting findings were also observed in patients in IT, IC, LR
and reactivation phases. Among the 32 ETV-treated patients in
IC phase who undergone a second liver biopsy, the decline of
intrahepatic cccDNA was accompanied by changes in both
qHBcrAg and qHBsAg. However, as compared to qHBsAg,
the dynamic change of qHBcrAg was more strongly associated
with intrahepatic cccDNA-decline (r=0.665, P<0.001 for qHBcrAg;
and r=0.572, P=0.001 for qHBsAg). Conclusions: As
compared to either qHBsAg or HBV DNA, serum qHBcrAg has
a better positive correlation with intrahepatic cccDNA. And
serum qHBcrAg should be a good surrogate of intrahepatic
cccDNA of HBV.
The correlations of serum qHBcrAg (A), qHBsAg (B) and HBV
DNA (C) with intrahepatic cccDNA among different phases of
CHB.
Disclosures:
The following people have nothing to disclose: En-Qiang Chen, Shu Feng,
Ling-Bo Liang, Ling-Yun Zhou, Ling-Yao Du, Li-Bo Yan, Meng-Lan Wang, Chuan-
Min Tao, Hong Tang

StephenW

577
AASLD2016 [
血清乙型肝炎核心相关抗原作为良好的替代品
肝内共价闭合标记
DNA在慢性乙型肝炎病毒的不同阶段
感染
陈强1，舒凤3，凌波梁1,2，林云云1,2，
凌玉耀1,2，李波波1,2，孟兰兰1,2，川敏涛3，
洪塘1,2; 1华西医院传染病中心
四川大学，成都，中国;传染性的2Division
四川大学生物治疗国家重点实验室，
中国成都西部实验室医学部
中国医院，四川大学，成都，中国
目的：本研究旨在探讨血清的相关性
定量乙型肝炎核心相关抗原（qHBcrAg）
肝内cccDNA在不同阶段的自然
慢性乙型肝炎病史（CHB），从而揭示是否
血清qHBcrAg可用作肝内的替代标记物
cccDNA。方法：共有139例CHB患者
进行肝活检，由59例患者组成
在免疫耐受（IT）期，52例免疫清除
（IC）期，20例在低复制（LR）期，和
8名患者在再活化期。所有患者在IC期有
接受恩替卡韦（ETV）治疗，其中32例经历
在24个月进行第二次肝活检。在本研究中，血清
qHBcrAg，qHBsAg，HBV DNA和肝内cccDNA水平
均定量测定。结果：在139
患者血清qHBcrAg呈强阳性相关
肝内cccDNA（r = 0.929，P <0.001），这是优越的
到血清qHBsAg（r = 0.742，P <0.001）和HBV DNA
（r = 0.854，P <0.001）与肝内cccDNA。和类似
在IT，IC，LR的患者中也观察到有趣的发现
和再活化阶段。在32例ETV治疗的患者中
IC期经历了第二次肝活检，下降
肝内cccDNA伴随两者的变化
qHBcrAg和qHBsAg。然而，与qHBsAg相比，
qHBcrAg的动态变化更强烈相关
肝内cccDNA下降（r = 0.665，qHBcrAg的P <0.001;
和r = 0.572，对于qHBsAg，P = 0.001）。结论：
与qHBsAg或HBV DNA，血清qHBcrAg相比
与肝内cccDNA更好的正相关。和
血清qHBcrAg应该是肝内的良好替代物
HBV的cccDNA。
血清qHBcrAg（A），qHBsAg（B）和HBV的相关性
DNA（C）与肝内cccDNA在不同阶段
CHB。
披露：
以下人士没有透露：陈展强，
凌波梁，周凌云，林玉耀，李波燕，孟兰兰，川 -
闵陶，洪唐